Fibromyalgia (Fibromyalgia Syndrome) Pipeline Review, H2 2020: Therapeutic Analysis of 18 Companies & Drug Profiles - ResearchAndMarkets.com

·3-min read

The "Fibromyalgia (Fibromyalgia Syndrome) - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Fibromyalgia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Fibromyalgia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibromyalgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fibromyalgia (Fibromyalgia Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 8, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Fibromyalgia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Fibromyalgia (Central Nervous System).

  • The pipeline guide reviews pipeline therapeutics for Fibromyalgia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Fibromyalgia (Central Nervous System) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Fibromyalgia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Fibromyalgia (Central Nervous System)

Key Topics Covered:

Introduction

Fibromyalgia (Fibromyalgia Syndrome) - Overview

Fibromyalgia (Fibromyalgia Syndrome) - Therapeutics Development

Fibromyalgia (Fibromyalgia Syndrome) - Therapeutics Assessment

Fibromyalgia (Fibromyalgia Syndrome) - Companies Involved in Therapeutics Development

Fibromyalgia (Fibromyalgia Syndrome) - Drug Profiles

Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects

Fibromyalgia (Fibromyalgia Syndrome) - Discontinued Products

Fibromyalgia (Fibromyalgia Syndrome) - Product Development Milestones

Appendix

Companies Mentioned

  • Aptinyx Inc

  • Cortene Inc

  • Cytocom Inc

  • Epitech Group SpA

  • H. Lundbeck AS

  • Imbrium Therapeutics LP

  • Innovative Med Concepts LLC

  • Intec Pharma Ltd

  • Jiangsu Hengrui Medicine Co Ltd

  • Luye Pharma Group Ltd

  • NeuroCycle Therapeutics Inc

  • One World Cannabis Ltd

  • Pfizer Inc

  • PRISM Pharma Co Ltd

  • Reven Pharmaceuticals Inc

  • Tetra Bio-Pharma Inc

  • Teva Pharmaceutical Industries Ltd

  • Tonix Pharmaceuticals Holding Corp

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/1jis7h

View source version on businesswire.com: https://www.businesswire.com/news/home/20201029006059/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900